drugset / Trial / NCT01540071
Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.
Timeline
- Start
- 2011-08
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IRX4204 | Small molecule | 20 mg | Oral |